Exact Sciences (EXAS) Tops Q2 EPS by 5c

Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.58), $0.05 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $268.9 million versus the consensus estimate of $228.42 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• L3Harris CEO steps down amid conduct review, shares drop
• BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c